BUWA Stock Overview
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$516.60 |
| 52 Week High | US$690.00 |
| 52 Week Low | US$444.20 |
| Beta | 0.92 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -22.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1,048.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BUWA | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | -1.4% |
| 1Y | -22.9% | -11.5% | 2.2% |
Return vs Industry: BUWA matched the German Life Sciences industry which returned -23.6% over the past year.
Return vs Market: BUWA underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| BUWA volatility | |
|---|---|
| BUWA Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BUWA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BUWA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 7,900 | Norman Schwartz | www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Bio-Rad Laboratories, Inc. Fundamentals Summary
| BUWA fundamental statistics | |
|---|---|
| Market cap | €12.12b |
| Earnings (TTM) | -€5.81b |
| Revenue (TTM) | €2.70b |
4.5x
P/S Ratio-2.1x
P/E RatioIs BUWA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BUWA income statement (TTM) | |
|---|---|
| Revenue | US$2.80b |
| Cost of Revenue | US$1.20b |
| Gross Profit | US$1.60b |
| Other Expenses | US$7.64b |
| Earnings | -US$6.03b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -202.34 |
| Gross Margin | 57.07% |
| Net Profit Margin | -215.16% |
| Debt/Equity Ratio | 14.0% |
How did BUWA perform over the long term?
See historical performance and comparison